Keywords
hyperprolactinemia
etiology
prolactinoma
drugs
How to Cite
Abstract
Hyperprolactinemia is a common cause of endocrinological consultation related to multiple etiologies: physiological, pharmacological, and pathological of the sellar and suprasellar region.
References
Melmed, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guidelin. JCEM 2011. 96:273-288.
George A. Scangas. Edward R. Laws Jr. Pituitary incidentalomas. Pituitary (2014) 17:486–491 DOI 10.1007/s11102-013-0517-x.
Halperin Rabinovich I, Cámara Gómez R, García Mouriz M, Ollero García- Agulló D. Guía clínica de diagnóstico y tratamiento del prolactinoma y la hiperprolactinemia. Endocrinología y Nutrición, 2013. 60(6): 308-319.
Bozza L, Belardo A. Manejo de la hiperprolactinemia en la mujer. Revista SAEGRE- Volumen XXII-N°1- abril 2015 :51-57.
Abbara A Clarke S Nesbitt A. Ali S. Comninos A Hatfield E. Martin N. Sam A. Meeran K Dhillo W. Interpretation of serum gonadotropin levels in hyperprolactinemia. Neuroendocrinology (2018).
Saleem M, martin H, Coates P. Prolactin Biology and laboratory Measurement: an Update on Physiology and Current Analytical issues. Clin Biochem Rev 2018; 39: 3-16.
Shlomo Melmed. Pathogenesis of Pituiter Tumors. Nature Reviews Endocrinology. Vol7 2001.257-266.
Andrea Glezer and Marcello D. Bronstein. Approach to the Patient with Persistent Hyperprolactinemia and Negative Sellar Imaging. J Clin Endocrinol Metab, July 2012, 97(7):2211–2216.
Bronstein M, Glezer A. Prolactinomas. Endocrinol Metab Clin N Am 44 (2015) 71-78.
Mark E. Molitch. Management of Incidentally Found Nonfunctional Pituitary Tumors” Neurosurgery. Clin N Am 23 (2012) 543–553.
Vilar L, Freitas Vilar C, lyra R, Freitas MDC. Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology 2019; 109: 7-19.
Fleseriu M. Drugs and pituitary function. Melmed S, The Pituitary. 4th ed. Academic Press, San Diego, 2017, p 383-96.
Danilowicz K, Mana D, Rizzo L. Impacto de la Prolactina en psiquiatría. Separata Montpellier 2021-Vol 29 N°6; 1-36.
Molitch ME. Drugs and Prolactin. Pituitary 2008; 11:209-18
Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28:421-53.
Sosa-Eroza E, Cuevas-Ramos D, Domínguez B, Espinosa-Cárdenas E et al. Prolactinoma and hyperprolactinemia.Psitioning of the SMNE. Rev mex Endocrinol Metab Nutr. 2023;10 (supl1): 45-69.
Calarge CA, Mills JA, Ziegler EE, Schlechte JA. Calcium and vitamin D Supplementation in Boys with Risperidone-induced Hyperprolactinemia: A Randomized, Placebo- Controlled Pilot srudy. J Chuil Adolesc Psychopharmacol 2018; 28: 145-50.
Cavallaro R, Cocchio F, Angelone SM, Lattuada E, Smeraldi E. cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004; 65: 187-90.
Tollin R. Use of the dopamine agonist bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000; 23: 765-70.
Montejo AL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front neuroendocrinol 2017; 45: 25-34.
F Donadio , A Barbieri, R Angioni, G Mantovani, P Beck-Peccoz, A Spada, A G Lania. Patiens with Macroprolactinemia: Clinical and radiological features. Eur J Clin Invest (2007) 37: 552-557.
Petersenn S. biochemical diagnosis in prolactinomas: some caveats. Pituitary2019 Dec 23. Doi:10.1007/s11102-019-01024-z.
Esta obra está bajo licencia internacional
